Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 3/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.58 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indoramin SCHEMBL29370437 | 1.00 | ADRA1D (1.00) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL123678 | 0.99 | ADRA1D (0.98) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL29801648 | 0.99 | ADRA1D (0.98) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Indoramin SCHEMBL1651262 | 0.98 | ADRA1D (0.96) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11303310 | 0.92 | ADRA2A (0.85) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11506582 | 0.92 | ADRA2A (0.85) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11545710 | 0.91 | ADRA2A (0.83) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL11545694 | 0.91 | ADRA2A (0.83) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL11070428 | 0.90 | ADRA2A (0.81) | ADRA1DADRA1AADRA1BADRA2AADRA2B | |
| SCHEMBL10783732 | 0.89 | ADRA2A (0.80) | ADRA1DADRA1AADRA1BADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6530 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-12472158-B2 | Methods of treating trigeminal nerve pain | VANDERBILT UNIVERSITY (US) | 2025-11-18 | — | — | US | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| US-20250222008-A1 | EYEDROPS CONTAINING AN ALPHA1-BLOCKER FOR INHIBITING MYOPIA PROGRESSION | TSUBOTA LABORATORY, INC. (JP) | 2025-07-10 | — | — | US | claimed |
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| US-20250120907-A1 | Transmucosal Drug Delivery System | Masiz, John J. (US) | 2025-04-17 | — | — | US | claimed |
| US-12246098-B2 | Trans-epithelial membrane drug delivery system | BioPhysics Pharma, Inc. (US) | 2025-03-11 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-0193427-A1 | Warhead with shaped charges arranged in tandem | ETAT-FRANCAIS représenté par le DELEGUE GENERAL POUR L'ARMEMENT (DPAG) (FR) | 1986-09-03 | — | — | EP | claimed |
| US-4607042-A | 3-(2-(4-BENZAMIDO-1-PIPERIDYL)ETHYL)INDOLE | JOHN WYETH & BROTHER LTD. (GB) | 1986-08-19 | — | — | US | claimed |
| EP-0067539-B1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION | JOHN WYETH & BROTHER LIMITED (GB) | 1985-09-18 | — | — | EP | claimed |
| EP-0154553-A2 | Use of compounds for increasing plasma high density lipoprotein cholesterol | JOHN WYETH & BROTHER LIMITED (GB) | 1985-09-11 | — | — | EP | claimed |
| US-4524060-A | PELLET MIXTURE OF INDORAMIN, CELLULOSE, AND WETTING AGENT IN GASTRIC JUICE PERMEABLE COATINGS | JOHN WYETH & BROTHER LIMITED (GB) | 1985-06-18 | — | — | US | claimed |
| US-4428954-A | CHARACTERIZED BY POOR OXYGENATION | JOHN WYETH AND BROTHER LIMITED (GB) | 1984-01-31 | — | — | US | claimed |
| EP-0067539-A2 | Sustained release pharmaceutical composition | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | claimed |
| US-4223008-A | HYPOTENSIVE | JOHN WYETH & BROTHER LIMITED (GB) | 1980-09-16 | — | — | US | claimed |
| US-4162252-A | Process for preparing 3-[(benzamidopiperid-1-yl)alkyl] indoles | JOHN WYETH & BROTHER LIMITED (GB) | 1979-07-24 | — | — | US | claimed |
| US-4140691-A | Process for preparing 3-[2-(4-benzamidopiperid-1-yl)ethyl]indole | JOHN WYETH & BROTHER, LTD. (GB) | 1979-02-20 | — | — | US | claimed |